About me

Associate professor (Docent) in Immunology, Karolinska Institutet.

Since February 2023, group leader, Karolinska Institutet, Dept. of Clinical Science, Intervention and Technology.

April 2019 - January 2023, Senior researcher, deputy group leader, Karolinska Institutet, Dept. of Oncology Pathology.

April 2015 - March 2019, Assistant professor, Karolinska Institutet, Dept. of Oncology Pathology.

September 2013 - March 2015, Postdoctoral fellow, U1016 INSERM, Institut Cochin, Dept. of Endocrinology, Metabolism and Diabetes (Paris, France).

September 2010 - August 2013, Researcher, Karolinska University Hospital Huddinge & Karolinska Institutet, Dept. of Laboratory Medicine.

June 2009 - August 2010, Postdoctoral fellow, Karolinska Institutet, Dept. of Microbiology, Tumor and Cell Biology.

2005-2009, PhD in Immunobiology, Karolinska Institutet, Dept. of Microbiology, Tumor and Cellular Biology. Thesis title: “CD8alpha/alpha+ T-cells and Immune Memory”. https://openarchive.ki.se/xmlui/handle/10616/39450

Research description

My goal is to contribute to the improvement of chimeric antigen receptor (CAR) T cell therapy for the treatment of cancer. Our group is working on the development of mesothelin (MSLN) CAR T cell therapy for the treatment of ovarian cancer. A preclinical model of orthotopic ovarian cancer in mice has been established in our group, which allows to test in vivo the antitumor efficacy of MSLN CAR T cells.

Recent publications:

Schoutrop E, Poiret T, El-Serafi I, Zhao Y, He R, Moter A, Henriksson J, Hassan M, Magalhaes I*, Mattsson J*. Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models. J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-005691. 

Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, Magalhaes I. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Semin Cancer Biol. 2022 Nov;86(Pt 3):207-223. doi: 10.1016/j.semcancer.2022.03.027.

Schoutrop E, Renken S, Micallef Nilsson I, Hahn P, Poiret T, Kiessling R, Wickström SL, Mattsson J, Magalhaes I. Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality. Oncoimmunology. 2022;11(1):2093426. doi: 10.1080/2162402X.2022.2093426.

Renken S, Nakajima T, Magalhaes I, Mattsson J, Lundqvist A, Arnér ESJ, Kiessling R, Wickström SL. Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress. J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2021-004458. 

Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L, Carlson JW, Lehti K, Hassan M, Magalhaes I*, Mattsson J*. Mesothelin-Specific CAR T Cells Target Ovarian Cancer. Cancer Res. 2021 Jun 1;81(11):3022-3035. doi: 10.1158/0008-5472.CAN-20-2701. 

Magalhaes I, Fernebro J, Abd Own S, Glaessgen D, Corvigno S, Remberger M, Mattsson J, Dahlstrand H. Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor. Adv Ther. 2020 Dec;37(12):5023-5031. doi: 10.1007/s12325-020-01520-w. 

Teaching portfolio

I organize since 2016 the Antigen Presentation and T Cell Activation doctoral course (Karolinska Institutet #2363).



2002, Master in Immunology (Diplôme d’études approfondies), Paris VII University & Institut Pasteur (Paris, France).

2000, Bachelor in Cellular Biology and Physiology, Rennes II University (Rennes, France).

Academic honours, awards and prizes

Fellowship in Ovarian Cancer Research from Cancerfonden (2019-2022).